Table 4

Univariate and multivariate analysis of the impact of the frailty profile of patients on OS, PFS, discontinuation rate, and incidence of grade 3 or higher toxicity

OSPFSDiscontinuationGrade ≥3 hematologic toxicityGrade ≥3 nonhematologic toxicity
HR (95% CI)PHR (95% CI)PHR (95% CI)PHR (95% CI)PHR (95% CI)P
Crude
 Fit11111
 Intermediate fitness1.61 (1.02-2.56).0421.18 (0.91-1.53).2111.48 (1.05-2.10).0260.97 (0.74-1.27).8081.23 (0.89-1.71).217
 Frail3.57 (2.37-5.39)<.0011.68 (1.31-2.15)<.0012.27 (1.64-3.14)<.0010.83 (0.62-1.09).1811.74 (1.28-2.38)<.001
Adjusted*
 Fit11111
 Intermediate fitness1.37 (0.86-2.18).1811.08 (0.83-1.40).5831.41 (1.00-2.01).0520.97 (0.74-1.28).8311.13 (0.81-1.58).462
 Frail2.88 (1.88-4.40)<.0011.48 (1.15-1.92).0032.21 (1.57-3.09)<.0010.94 (0.71-1.26).6981.57 (1.12-2.19).008
  • * Adjusted for ISS, chromosome abnormalities, and therapy.